Bay Area-based pharmaceutical company Verseon has been a quiet pioneer in computational drug design since 2002, predating the widespread emergence…
Read More
Johnson & Johnson’s Spravato Remission Data Takes Center Stage in Push for Treatment-Resistant Depression Growth
A recent poster presentation at Psych Congress Elevate by Johnson & Johnson has placed esketamine nasal spray, marketed as Spravato,…
Read More
UK Recommends Routine Meningitis B Vaccination for Adolescents Following Data Review
The UK’s Joint Committee on Vaccination and Immunisation (JCVI) has put forth a significant recommendation for the introduction of a…
Read More
Innovations in AI, Data Science, and Python Architecture Dominate Mid-July 2026 Discussions
The week of July 13-17, 2026, marked a significant period for insights into the rapidly evolving fields of Artificial Intelligence,…
Read More
Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo
Eli Lilly and Company has announced groundbreaking Phase 3 results for its investigational triple agonist, retatrutide, demonstrating significant efficacy in…
Read More
Benchmarking Data Analysis Prowess: SQL, Pandas, and AI Agents Under Scrutiny
A recent comprehensive study has rigorously benchmarked the performance and capabilities of three dominant forces in data analysis—Structured Query Language…
Read More
5 Real-World SQL Projects to Build Your Data Portfolio
SQL remains a cornerstone skill for professionals across the data landscape, from data analysts and scientists to business intelligence specialists…
Read More
J&J Positions Spravato Remission Data at Forefront of Treatment-Resistant Depression Growth Strategy
Johnson & Johnson (J&J) is intensifying its marketing efforts for Spravato (esketamine) by spotlighting compelling remission rate data for treatment-resistant…
Read More
Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo
Eli Lilly has significantly bolstered its position in the competitive metabolic disease landscape with detailed Phase 3 results for its…
Read More
The biotech bi-weekly: a disease modeling research grant and an accelerator program for data-driven health start-ups
The biotech sector continues its rapid evolution, marked this week by advancements poised to streamline laboratory processes, democratize powerful AI…
Read MoreYOU MAY HAVE MISSED
